Second-generation drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. Besides the polymer and antiproliferative drug used, the metallic backbone of DES is an attractive target for further development. Ultrathin-strut DES (≤70 µm strut thickness) are more flexible, have an improved trackability and crossability compared to conventional second-generation DES. Importantly, ultrathin-strut DES reduce the risk of in-stent restenosis, thereby decreasing the risk of angiographic and clinical restenosis. In this narrative review, we will discuss the clinical outcomes of the commercially available ultrathin-strut DES.

The first coronary stent was implanted by Sigwart and Puel in 1986. Coronary stents were initially used to treat failure of balloon angioplasty treatment, i.e. as bail-out for acute vessel closure (due to dissections) or restenosis (due to elastic recoil). After the BENESTENT and STRESS landmark randomized trials, the routine use of coronary stents for percutaneous treatment of coronary artery disease became common practice. A major drawback of these coronary stents was angiographic in-stent restenosis (ISR) caused by increased neo-intimal hyperplasia (NIH), which led to recurrent ischaemic symptoms and repeat revascularizations in up to 25% of patients after stent implantation. Coronary stents were therefore further improved by drug elution from a polymer coating. Drug-eluting stents (DES), compared with coronary stents without an antiproliferative drug coating (nowadays referred to as ‘bare metal stents’ [BMS]), reduced NIH, thereby reducing the need for repeat revascularizations. The downside of these first-generation DES was the increased incidence of very late stent thrombosis. This could be explained by delayed and/or incomplete endothelialization and hypersensitivity response to the polymer coating with inflammation of the endothelium. To reduce the rate of very late stent thrombosis, second-generation DES were developed with biocompatible and biodegradable polymers, or even polymer free.

Although the above-mentioned developments led to major improvements in clinical outcomes, manufacturers are still advancing DES. Besides the polymer and antiproliferative drug used, the metallic backbone of DES is an attractive target for further development. The metallic backbone plays a crucial role in device handling, but also safety and efficacy. This narrative review aims to elucidate the role of the metallic backbone on DES performance, with a specific focus on the strut thickness. Recent stents with ultrathin strut thickness (≤70 µm) have been developed to improve clinical outcomes after percutaneous coronary intervention (PCI). We will discuss the potential advantages and disadvantages of ultrathin struts and discuss the clinical data available.

Potential advantages of ultrathin struts
Positive impact of thin struts on early vessel healing
Although the antiproliferative drug of first-generation DES has resulted in less NIH compared to bare-metal stents, it also impaired vascular healing, resulting in delayed and incomplete endothelialization. In addition, the presence of permanent polymers might contribute to delayed healing due to hypersensitivity reactions. As a result, blood flow is exposed to thrombogenic stent struts, potentially leading to stent thrombosis. Furthermore, delaying the time needed for complete stent strut endothelialization, i.e. restoration of endothelial continuity, might stagnate vessel healing with consequently increased NIH formation. These factors may contribute to developing ISR, but also neo-atherosclerosis, leading to repeat revascularizations. Timely re-endothelialization is therefore important.

Preclinical data have shown the impact of strut thickness on vessel healing after stent implantation. In a rabbit denudation model, strut coverage at day 14 was as high as 95% in the stents with the thinnest struts (81 µm) and lower with thicker struts: 88% in stents with struts of...
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?

In vivo study in a porcine model using optical coherence tomography (OCT) showed faster and better strut coverage of the stent with the thinnest struts (61 μm). After 1 week, only 1.6% of the struts were uncovered in the stent with the 61 μm struts, while 6.6% of struts were uncovered of the stent with the 81 μm struts, and as high as 48.4% of struts were uncovered of the stent with the 141 μm struts. At week 4, the stent with the thinnest struts showed a mean coverage thickness of 0.14 mm, compared with 0.13 mm (stent with 81 μm struts) and 0.12 mm (stent with 141 μm struts). Delayed endothelialization and increased risk of restenosis with thicker struts might be explained by the larger surface taking more time to endothelialize. Furthermore, thicker struts might cause more vessel injury and local inflammation due to the penetrating stent struts traumatically disrupting the internal elastic lamina. This increased intimal inflammation with thicker struts may promote neo-intimal growth and hyperplasia, leading to restenosis.

Another preclinical study using ex vivo flow loops showed that stents with a strut thickness of 162 μm compared with otherwise identical stents with strut thickness of 81 μm were 1.5 times more thrombogenic. In the same study, both stents were implanted in porcine coronary arteries, showing more thrombus and fibrin deposition 3 days after implantation in the thick-strut stent. It has been postulated that strut thickness modulates local blood flow, with local stagnation and recirculation of blood flow in thick struts (Figure 1). This leads to areas of lower endothelial shear stress (ESS). Areas of lower ESS are more prone to platelet aggregation (hence thrombosis), but also determine neo-intima formation.

How does the above affect clinical outcomes in patients treated with coronary stents? Earlier clinical data from the ISAR-STEREO trial showed the influence of strut thickness on ISR rates. A total of 651 patients were randomized to receive a thin-strut stent (50 μm) or an otherwise comparable stent with strut thickness of 140 μm, both without a polymer or antiproliferative drug. Incidence of angiographic restenosis (defined as >50% stenosis at 6-month follow-up angiography) was almost twice as high in the thick-strut group compared with the thin-strut group (15.0% versus 25.8%, respectively, relative risk, 0.58; 95% confidence interval [CI], 0.39–0.87; p=0.003). This resulted in differences in clinical restenosis rates, with a repeat intervention performed in 8.6% in the thin-strut group and 13.8% in the thick-strut group (relative risk, 0.62; 95% CI, 0.39–0.99; p=0.03). This proved the direct influence of strut thickness on the risk of ISR, with thinner struts decreasing the risk of angiographic and clinical restenosis (although the latter might be partly driven by the 'occulo-stenotic reflex'). We have observed similar findings in an observational study from our own.
A meta-regression analysis of DES showed a correlation between strut thickness and ‘late lumen loss’ more than 0.50 mm, an angiographic outcome that predicts repeat revascularization. Finally, strut thickness has been conversely associated with stent thrombosis, i.e. stents with thinner struts are less prone to stent thrombosis compared to conventional second-generation DES.

In summary, preclinical data have shown improved vessel healing and less thrombogenicity with thinner struts compared with thicker struts. Clinical data from a meta-analysis have shown that thinner struts may lead to improved clinical outcomes.

**Positive impact of ultrathin struts on the mechanical properties and deliverability of drug-eluting stents**

The mechanical behaviour of stents is important for each of the stent ‘life phases’, which could be categorized as 1) manufacturing and packaging; 2) delivery; 3) deployment; and 4) in vivo function. Although studies on deployment and especially in vivo function (i.e. angiographic, intravascular imaging and clinical outcome data) are countless, data on mechanical behaviour during delivery of the stent are sparse. Deliverability is characterized by the pushability, trackability and crossability of the stent delivery system, and varies among DES.

Although, to the best of our knowledge, no formal tests have been published on deliverability parameters of stents with ultrathin struts, ultrathin struts are presumably more flexible, improving trackability, and have a lower profile, improving crossability compared to conventional second-generation DES.

**Negative impact of ultrathin struts on the mechanical properties of drug-eluting stents**

Coronary stents should be able to resist high external pressures to maintain lumen patency. In a healthy coronary artery, this is approximately 200 mmHg. In a calcified lesion however, the external pressure on the stent is much higher. Failing to resist the (chronic) external pressure may lead to ISR. This resistance to this external force is dictated by the stent’s radial stiffness, defined as a change in stent diameter due to uniformly applied external radial force, and radial strength, defined as the pressure that permanently deforms the stent.

The type of metal used, strut thickness and architecture of the stent determine radial strength. Stainless steel has been the primary component of the metallic backbone since the first coronary stents, with 316L surgical steel being the most widely used. Cobalt–chromium alloys have brought some advances over stainless steel. Due to a higher elastic modulus and tensile strength, radial strength is better with cobalt–chromium than with stainless steel, which has enabled the use of thinner struts without compromising the radial strength. The most commonly used cobalt–chromium alloy is L605. Alternatively, platinum–chromium platforms have been developed by adding platinum to 316L stainless steel, with comparable mechanical properties to cobalt–chromium, also allowing the use of thinner struts.

Stent architecture also affects radial strength. Current stent architecture can be sub-classified into four categories: coils, slotted tubes, helical and modular designs. Most contemporary stents are modular, consisting of undulated rings. These rings (or ‘hoops’) are fused together by ‘connectors’, which provide the longitudinal support of the stent. The number of connectors between two rings, and their orientation, plays a major role in the mechanical properties of coronary stents. The more connectors, the smaller the ‘stent cell’ (defined as the area enclosed by two connectors and two adjacent rings), which results in a closed-cell design. On the other hand, having fewer connectors results in larger stent cells and an open-cell design. A closed-cell design provides better vessel wall coverage with less prolapse of plaque compared with an open-cell design. In one animal model, better coverage with less prolapse of plaque resulted in a smoother luminal contour and less platelet activation. Better coverage with less thrombus protrusion resulted in less distal embolization in patients with ST-elevation myocardial infarction (STEMI). Closed-cell designs also provide better radial strength than open-cell designs. However, open-cell designs have better flexibility, deliverability and conformability than closed-cell designs. Moreover, they provide easier access to side branches in bifurcation lesions.

Low radial strength may result in stent recoil. Acute stent recoil is defined as a difference in diameter of the stent delivery balloon at the highest used pressure during implantation and the actual measured mean luminal stent diameter after implantation. Acute stent recoil results in residual stenosis associated with ISR and repeat revascularization.
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?

Table 1: Overview of currently available stents with ultrathin struts

| Stent name               | Manufacturer               | Material         | Strut thickness (µm) | Coating thickness (µm) | Drug used (dose) | Drug coating | Cell design     | Polymer                        | Drug release kinetics |
|--------------------------|----------------------------|------------------|---------------------|------------------------|------------------|--------------|----------------|--------------------------------|-----------------------|
| Orsiro®                 | Biotronik                  | Cobalt–chromium | 60                  | Abluminal 7.5, luminal 3.5 | Sirolimus (1.4 µg/mm²) | Circumferential (asymmetrical) | Open             | Amorphous silicon carbide coating and BioOut® PLLA | ~100 days |
| MiStent™                | Micell                     | Cobalt–chromium | 64                  | Abluminal 15, luminal 5  | Sirolimus (2.44 µg/mm²) | Circumferential (asymmetrical) | Open             | PLGA                          | 50% at 30 days, complete at 9 months |
| BioMime™/BioMime™ Morph | Meril                      | Cobalt–chromium | 65                  | 2                      | Sirolimus (1.25 µg/mm²) | Circumferential (asymmetrical) | Open and closed | PLLA + PLGA                     | ~98% at 30 days |
| Supraflex™/Cruz         | Sahajanand                 | Cobalt–chromium | 60                  | 5–6                    | Sirolimus (1.4 µg/mm²) | Circumferential (asymmetrical) | Open             | PLLA, PLCL, PVP                  | 70% at 7 days, complete at 48 days |
| Tetriflex™              | Sahajanand                 | Cobalt–chromium | 60                  | 4–6                    | Sirolimus (1.4 µg/mm²) | Circumferential (asymmetrical) | Open             | PLLA, 50/50 PDLGA, PVP          | 80% at 28 days, complete at ~90 days |
| Tetrilimus™             | Sahajanand                 | Cobalt–chromium | 60                  | 4–6                    | Everolimus (1.0 µg/mm²) | Circumferential (asymmetrical) | Open             | PLLA, PLCL, PVP                  | 80% at 28 days, complete at ~90 days |
| Eteroflex™              | Sahajanand                 | Cobalt–chromium | 60                  | 5–6                    | Everolimus (1.0 µg/mm²) | Circumferential (asymmetrical) | Open             | PLLA, PLCL, PVP                  | 70% at 7 days, complete at 48 days |

PDGLA = poly(D,L-lactide-co-glycolide); PLCL = poly-L-lactide-co-caprolactone; PLGA = poly-lactic-co-glycolic acid; PLLA = poly-L-lactic acid; PVP = poly-vinyl pyrrolidone.

To summarize, the type of metal used, strut thickness and architecture of the stent determine radial strength. Although thinner struts made of cobalt–chromium or platinum–chromium alloys have a radial strength comparable to those made with stainless steel, some clinical data suggest that the radial strength of stents with ultrathin struts might be insufficient for treating CTO lesions and might lead to more stent recoil compared to conventional second-generation DES. More studies are necessary, exploring other lesions (such as highly calcified lesions) in which a higher radial strength is likely needed.

**Overview of currently available stents with ultrathin struts**

Thin struts are arbitrarily defined as being <100 µm thick, whereas ultrathin struts are <70 µm thick. An overview of stents with ultrathin struts is given in Table 1, and is discussed below.

**Orsiro**

The Orsiro stent has a 60 µm strut thickness (80 µm when stent diameter >3 mm). The stent is made of a cobalt–chromium alloy and it elutes sirolimus from a biodegradable polymer, poly-L-lactic acid (PLLA). The polymer coverage is asymmetrical, with a thicker coating (and thus more drug release) on the abluminal side of the struts. The sirolimus is eluted over approximately 100 days. The design of the stent is different from other DES; whereas most DES have adjacent rings fused together by connectors, the Orsiro consists of two double helices (instead of separate rings), which are held together by connectors oriented in the mid-portion of each strut (Figure 2).

**MiStent**

The MiStent stent (Micell Technologies, Durham, NC, USA) has a 64 µm strut thickness and is made of a cobalt–chromium alloy. The stent coating consists of a poly-lactic-co-glycolic acid (PLGA) polymer loaded with microcrystalline particles of sirolimus. The coating is asymmetrical, with a thicker coating on the abluminal side (~15 µm) than on the luminal side (~5 µm) of the struts. The coating process of dry-powder crystalline sirolimus is solvent free and further differentiated by supercritical fluid
technology to apply the polymer component. While the polymer fully biodegrades within 3 months, the sirolimus remains in the surrounding tissue for up to 9 months to continuously inhibit neointimal tissue growth. The stent design consists of rings each connected by three interconnectors in an ‘off-set’ peak-to-peak fashion (Figure 2).

Supraflex™
The Supraflex™ stent (Sahajanand Medical Technologies, Mumbai, India) is made from L605 cobalt‒chromium alloy, and elutes sirolimus from a biodegradable polymer. The biodegradable polymer is a matrix coating consisting of PLLA with a 50:50 mixture of poly(D,L-lactide-coglycolide) (PLDLGA) and poly-vinyl pyrrolidone (PVP). The average polymer coating is 5–6 μm thick, and the polymer degrades gradually over 9–12 months. The stent strut thickness is 60 μm. Sirolimus is released over a short period of 48 days. The stent design consists of rings connected by two highly flexible S-link connectors (Figure 2). Sahajanand Medical Technologies also developed the Everoflex™ stent, comparable to Supraflex but with everolimus as the anti-proliferative drug. In addition, they developed the Supraflex™ Cruz stent, which is similar to the Supraflex except for the connectors between the rings and a different polymer coverage (Table 1). The Supraflex Cruz uses long dual L (LDZ) links, which are best described as in-phase valley-to-valley connections. Moreover, the company also manufactures the Tetriflex™ stent, similar in design to the Supraflex Cruz but with different polymers used (three separate thin layers of biodegradable polymer). Finally, the Tetrilimus™ stent has a comparable stent design to the Tetriflex stent design, with three layers of polymer, but with everolimus as the anti-proliferative drug.

BioMime™
The BioMime™ stent (Meril Life Sciences, Vapi, India) is made from L605 cobalt‒chromium alloy, and elutes sirolimus from the biocompatible and bioabsorbable polymers PLLA and PLGA. The coating is uniformly thin (2 μm), and degrades in approximately 6–9 months. The stent strut thickness is 65 μm. The stent design is a unique hybrid design of closed cells at the edges and an open-cell design in the mid-segment. The adjacent rings are connected with Y-connectors in the mid-section of the struts connected to each other by S-links (Figure 2). The company also developed the BioMime Morph™ stent, with stent lengths up to 60 mm with a tapered design, which is suitable for long lesions in tapered vessels, avoiding multiple stent uses with multiple overlap. In addition, they also developed the BioMime Branch™ stent, a dedicated bifurcation stent with ultrathin struts eluting sirolimus.

Clinical data on stents with ultrathin struts
Although strut thickness is likely to influence clinical outcomes of PCI, it is impossible to disentangle the sole effect of reduced strut thickness from that of other stent components. As outlined earlier, the stent design, polymer and anti-proliferative drug are also essential factors that determine outcome. In this section, we will provide an overview of clinical data available for ultrathin-strut DES. These other factors must be considered when interpreting trial results and clinical outcomes.

Orsiro
The Orsiro stent is the most widely investigated ultrathin-strut stent available. In the BIOFLOW-II trial (NCT01356888), 452 patients from eight European countries were randomized 2:1 to the Orsiro (N=298) or Xience (N=154) stent, an everolimus-eluting stent with durable polymer and 81 μm strut thickness.32 Lesion length had to be <26 mm and main exclusion criteria were recent myocardial infarction (MI; <72 hours), unprotected left main coronary artery disease, three-vessel coronary artery disease and left ventricular ejection fraction <30%. The study showed non-inferiority of the Orsiro stent compared with the Xience stent with regard to ‘in-stent late loss’ at 9-month re-angiography (0.10 ± 0.32 mm (mean + SD) versus 0.11 ± 0.29 mm, respectively; p for non-inferiority <0.001). In the multicentre, intercontinental BIOFLOW-IV trial (NCT01939249), 575 patients were randomized 2:1 to the Orsiro or Xience stents.33 Inclusion and exclusion criteria were similar to those of BIOFLOW-II. The non-inferiority primary endpoint of target vessel failure (composite of cardiac death, target-vessel MI, emergent coronary artery bypass graft and clinically driven target-vessel revascularization (TVR) at 12 months was met: 5.5% in the Orsiro group versus 7.5% in the Xience group (p for non-inferiority <0.001). The BIOFLOW-V trial (NCT02389946) included 1,334 patients (from 13 countries in Asia, Europe and North America) who were randomized to Orsiro or Xience in a 1:1 fashion.34 Patients with up to two-vessel coronary artery disease were included, as well as those with non-ST segment elevation acute coronary syndrome (NSTEMI), if haemodynamically stable. Maximum lesion length was 36 mm. CTOs, bifurcation lesions, bypass graft lesions and ISR lesions of previous DES were not allowed. The primary endpoint was target-lesion failure (TLF; composite of cardiac death, target-vessel MI and ischaemia-driven TLR) at 2 years, which was significantly lower in the Orsiro group than the Xience group (7.5% versus 11.9%, respectively; p=0.015); this was mainly driven by a lower rate of target-vessel MI (5.3% versus 9.5%; p=0.01) and stent thrombosis (0.1% versus 1.0%; p=0.043) in the Orsiro group.35 Extended follow-up to 3 years showed similar findings: TLF was 8.2% for Orsiro and 13.6% for Xience (p=0.002), driven by lower target-vessel MI (5.0% versus 9.2%; p=0.003) and clinically driven TLR rates (3.2% versus 6.7%; p=0.006) in the Orsiro group. Definite/probable late or very late stent thrombosis rate was also significantly lower in the Orsiro group than the Xience group (0.1% versus 1.2%, respectively; p=0.018). In the BIOFLOW-VI (NCT01939249) randomized trial, 440 patients from 11 Chinese sites were randomized 1:1 to Orsiro or Xience.36 Up to two separate lesions were allowed, with a lesion length <36 mm and a target-vessel Thrombolysis In Myocardial Infarction (TIMI) flow grade of 2 or higher. Patients with previous MI within 7 days, left ventricular ejection fraction below 40%, left main stenosis, bifurcations with side branch of 2.5 mm or larger, or heavily thrombotic or calcified lesions were excluded. The study showed that Orsiro was non-inferior to Xience with regard to 9-month late lumen loss (mean difference -0.02 mm; p for non-inferiority <0.0001).

In the BIOSCIENCE trial (NCT01443104), 2,119 patients from nine centres in Switzerland were randomized to Orsiro or Xience.37 The trial had an ‘all-comers’ design with minimal exclusion criteria, allowing patients with acute coronary syndromes (53%), diabetes (24%), history of hypertension (68%) or renal failure (15%) to participate. There were no restrictions on number of lesions, number of vessels treated and lesion length. Both de novo and restenotic lesions in bypass grafts or previous stents were eligible. The primary endpoint was TLF (composite of cardiac death, target-vessel MI and clinically indicated TLR) at 12 months. The study showed non-inferiority of Orsiro with regard to this primary endpoint (6.5% versus 6.6%; p for non-inferiority <0.004). A significant interaction was found for the pre-specified stratified analyses of the primary endpoint favouring Orsiro in patients presenting with STEMI at 12 months (3.3% versus 8.7%, RR 0.38, 95% CI 0.16–0.91, p=0.024, p for interaction=0.014). Long-term (5 years) follow-up showed similar clinical outcomes in both groups.38 In the subsequent BIOSTEMI trial (NCT02579031), 1,300 patients presenting with STEMI were randomized in a 1:1 fashion to Orsiro or Xience. The primary endpoint of non-inferiority with regard to TLF...
In the SORT OUT VII trial (NCT01879358) was an all-comer (21% STEMI, 31% NSTE-ACS, 19% diabetes, 58% history of hypertension, 57% hypercholesterolaemia, 22% multi-vessel PCI, 4% CTO, 12% bifurcations), investigator-initiated, randomized controlled trial comparing the Orsiro stent with the Nobori™ stent (Terumo Corporation, Tokyo, Japan) in 2,525 patients from Denmark. The Nobori stent is comparable with Orsiro by eluting an antiproliferative drug (biolimus) from a biodegradable polymer (poly-D,L-lactic acid [PDLLA]). The major difference from Orsiro is its stent design (rings connected by two connectors) and its thicker struts (120 µm). In SORT OUT VII, the primary endpoint was TLF (composite of cardiac death, MI and TLR) at 12 months. At 12 months, the primary endpoint occurred in 3.8% in the Orsiro group and 4.6% in the Nobori group (p for non-inferiority <0.0001). The Orsiro stent was superior in terms of definite stent thrombosis (0.4% versus 1.2%; p=0.034), mostly due to difference in sub-acute stent thrombosis (i.e. stent thrombosis occurring between 24 hours and 30 days). At 3-year follow-up, clinical outcomes were comparable between the two stents, including definite stent thrombosis rates (1.0% versus 1.7%; 95% CI, 0.30–1.18). The COMBO stent has a 316-L stainless-steel platform, with a strut thickness of 81 µm. In total, 26% of patients underwent multi-vessel PCI, 5% underwent PCI for CTO, and 19% underwent PCI for a bifurcation lesion. The primary endpoint was the composite of cardiac death, target lesion-related MI or TLR at 1 year. At 1 year, the primary endpoint occurred in 5.0% of the BioFreedom group and 3.7% of the Orsiro group, not meeting the criteria for non-inferiority for the BioFreedom stent compared with the Orsiro (p for non-inferiority=0.14). TLR rate was significantly higher in the BioFreedom group than the Orsiro group (0.0% versus 1.6%, respectively; p=0.040). The primary endpoint was a composite of cardiac death, MI and TVR at 12 months. The non-inferiority criteria were not met for the BioFreedom group (0.0% versus 1.6%, respectively; p=0.040). Regarding the TLF endpoint (composite of cardiac death, target-vessel MI and TLR), clinical outcomes were comparable between the Orsiro and Resolute Integrity groups (2.4% versus 3.3%, respectively); however, the study was not adequately powered for clinical endpoints. Three-year clinical follow-up showed TLF rates of 4.7% (Orsiro) and 7.8% (Resolute Integrity) (p=0.232 by log-rank test). Stent thrombosis occurred in no patients in the Orsiro group and two patients in the Resolute integrity group (0.0% versus 1.6%, respectively; p=0.040). The ORIENT trial (NCT01826552) was a randomized controlled trial comparing angiographic outcomes with the Orsiro stent and the Resolute Integrity™ stent in 372 patients in eight centres in South Korea. Both coronary artery disease (53%) and acute coronary syndromes (13% non-STEMI, 9% STEMI) were allowed indications for PCI. There were no restrictions on lesion complexity; left main coronary artery disease (5%), CTOs (8%), bifurcation lesions (23%) and restenotic lesions (2%), among others, were allowed. The primary endpoint was non-inferiority for in-stent late lumen loss at 9-month follow-up. Orsiro was non-inferior to Resolute Integrity (median late lumen loss was 0.06 mm and 0.12 mm, respectively; p for non-inferiority <0.0001; p for superiority=0.205). Regarding the TLVF endpoint (composite of cardiac death, target-vessel MI and TVF), defined as a composite of cardiac death, target-related MI or clinically indicated TVR, at 12 months) was met, and occurred in 4.5% of the Orsiro group and 4.7% of the Resolute Orxyx group. Three-year follow-up showed similar results with no significant differences in TLVF (9.2% versus 8.9% in Resolute Orxyx and Orsiro, respectively; p=0.85).
In the multicentre, all-comers BIODEGRADE trial (NCT02299011), 2,341 patients were randomized to the Orsiro stent or the first-generation BioMatrix™/BioMatrix Flex™ stents (Biosensors Interventional Technologies, Singapore). The BioMatrix stent is made from stainless steel with a strut thickness of 120 µm, and elutes Biolimus from a poly-lactic acid biodegradable polymer.91 In BIODEGRADE, acute coronary syndrome was the most prevalent indication for PCI (67%). More than half of the patients (60%) had a history of hypertension, 27% underwent PCI for more than one target lesion, 5% underwent PCI for CTO and 15% had PCI for a bifurcation lesion. The primary endpoint was TLF (composite of cardiac death, target-vessel MI or ischaemia-driven TLR) at 18 months. The primary endpoint was met and occurred in 2.9% of the BioMatrix™ group and 2.1% of the Orsiro group (p for non-inferiority <0.001).

Finally, the above-described PRISON IV trial randomized 330 patients with a CTO, comparing the Orsiro stent with the Xience stent.92 The primary non-inferiority endpoint was in-segment late lumen loss at 9 months. Non-inferiority criteria were not met, with a numerically higher late lumen loss with Orsiro than with Xience (0.13 mm versus 0.02 mm, respectively; p for non-inferiority=0.11). Binary restenosis rates were higher in the Orsiro group, leading to a significantly higher TLR rate at 3 years.93

In conclusion, the Orsiro stent has been rigorously investigated in multiple randomized controlled trials worldwide and in very diverse populations, including in all-comers and in acute coronary syndrome-specific populations, showing that the Orsiro stent competes with second- and other third-generation DES.94–96 Orsiro was non-inferior in all the trials comparing with other contemporary DES (i.e. mainly Xience, but also Resolute, Synergy and BioMatrix), while some other newer DES (e.g. BioRe600d and Combo stents) have not always met noninferiority criteria when compared with Orsiro. In specific subgroups (e.g. STEMI), Orsiro might even be superior to second-generation DES, while in other subgroups (e.g. CTOs) Orsiro may be inferior.

MiStent

The MiStent stent has been investigated in the DESSOLVE trial programme. DESSOLVE I (NCT01247428) was a first-in-human study including 30 patients with stable or unstable angina pectoris (excluding patients with MI) with lesion length ≤23 mm and coronary diameter of 2.5–3.0 mm. Patients with complex type C lesions (according to the American College of Cardiology/American Heart Association classification) were excluded. The study showed low and stable late lumen loss at 18-month follow-up, with complete struts coverage on OCT and no stent thrombosis.97

In the DESSOLVE II trial (NCT01294748), 184 patients were randomized 2:1 to the MiStent stent and the Endeavor™ zotarolimus-eluting stent (Medtronic Cardiovascular, Santa Rosa, CA, USA) with a biocompatible BioInx™ polymer coating and a strut thickness of 91 µm.98 All patients underwent quantitative coronary angiography directly after implantation (baseline) and during re-angiography at 9-month follow-up. A subgroup was also analysed using OCT. Inclusion and exclusion criteria were similar to DESSOLVE I. The primary endpoint, superiority of MiStent in terms of late lumen loss at 9 months, was met (mean late lumen loss 0.27 ± 0.46 mm in 103 patients with the MiStent versus 0.58 ± 0.41 mm in 52 patients with the Endeavor; p=0.001). The proportion of uncovered struts on OCT at 9 months was very low in both groups, but statistically significantly lower in the Endeavor group (2.1% in MiStent versus 0.5% in Endeavor; p=0.048).99 Long-term (5 years) follow-up data from both trials showed comparable clinical outcomes between both stents. The major adverse cardiac event (MACE) rate, defined as a composite of any death, MI or clinically driven TVR, was 15.1% in the MiStent group versus 22.0% in the Endeavor group (p=0.295).100 TVR and TLR rates were similar between groups. Definite/probable stent thrombosis rates were low in both groups, but numerically lower in the MiStent group (0.0% MiStent versus 1.7% Endeavor). However, DESSOLVE II was not designed for and thus not adequately powered for assessing clinical endpoints.101

The DESSOLVE III trial (NCT02385279) was therefore designed and powered to assess clinical endpoints. The DESSOLVE III trial was a multicentre, international, all-comers randomized trial including 1,398 patients throughout Europe.102 Patients were randomized 1:1 to either MiStent or Xience. With its all-comers design, acute coronary syndrome and stable coronary artery disease were both allowed indications for PCI: 15% of patients presented with STEMI, 20% with non-STEMI, 27% had diabetes, 74% had a history of hypertension, 61% had hypercholesterolaemia, 10% had established peripheral vascular disease and 7% had renal insufficiency. Average lesions per patient was 1.5; 7% had PCI for a bifurcation lesion and 3% had PCI for restenotic lesions. The primary endpoint was the non-inferiority of the MiStent regarding a device-oriented composite endpoint of cardiac death, target-vessel MI or clinically indicated TLR at 12 months. At 12 months, the device-oriented outcome had occurred in 5.8% of the MiStent group and 6.5% of the Xience group, meeting the non-inferiority criteria (p for non-inferiority=0.0001). Individual components of the composite endpoint were similar in both groups. Stent thrombosis rates were low and comparable between groups (definite/probable stent thrombosis rates were 0.7% and 0.9% in the MiStent and Xience groups, respectively).103 Two-year follow-up of the trial showed similar findings. The device-oriented outcomes occurred in 8.7% in the MiStent group and 8.6% in the Xience group (p=0.958).104 At 3-year follow-up, the device-oriented composite endpoint occurred in 10.5% of the MiStent group and 11.5% of the Xience group (p=0.55). Between the MiStent and Xience groups, cardiac death rates (3.9% versus 3.8%, respectively; p=0.88), target-vessel MI rates (3.2% versus 2.5%, respectively; p=0.43) and clinically indicated TLR rates (5.2% versus 6.5%, respectively; p=0.30) were not significantly different. Again, definite/probable stent thrombosis was infrequent (1.2% versus 1.5%, respectively; p=0.64).105

The DESSOLVE trial programme showed the safety and efficacy of the MiStent stent compared with the second-generation Xience stent.

Supraflex™

The FLEX Registry showed few adverse clinical outcomes with the Supraflex stent at 12 months, MACE, defined as the composite of cardiac death, MI and TVR, occurred in 3.7% of 995 unselected (i.e. ‘all-comers’) patients in nine different centres in India.106 Strut coverage, as assessed with OCT at 6 months’ follow-up, was excellent.

Subsequently, the prospective, randomized, multicentre TALENT trial (NCT02870140) was conducted throughout Europe.107 A total of 1,435 patients were randomized 1:1 to either Supraflex or Xience. More than half (59%) of the patients had acute coronary syndrome as initial diagnosis, of whom 16% had STEMI. Around one-quarter (23%) had diabetes, 66% had a history of hypertension, 61% had hypercholesterolaemia, 8% had established peripheral vascular disease and only 2% had renal insufficiency. Left main stenting was infrequent (1.5%), and the average number of lesions per patient was 1.4, 16% had PCI for a bifurcation lesion and 4% had PCI for restenotic lesions. The primary endpoint was non-inferiority of the Supraflex stent to the Xience stent with regard to a device-oriented composite endpoint of cardiac death, target-vessel MI or clinically indicated TLR at 12-month follow-up. The primary
device-oriented outcome had occurred in 4.9% of the Supraflex group and 5.3% of the Xience group (p for non-inferiority <0.0001) at 12 months. There were no between-group differences in individual clinical endpoints except for any death, which was higher in the Supraflex group than the Xience group (2.0% versus 0.6%, respectively; p=0.019). However, cardiac death rates were similar (1.0% versus 0.3%, respectively; p=0.097). Definite/probable ST rates were very low in both groups (0.8% versus 0.9%, respectively; p=0.996). At 2-year follow-up, the device-oriented composite endpoint had occurred in 6.9% of the Supraflex group and 7.9% of the Xience group (p=0.491). Rates of any death (2.5% versus 3.0%, respectively; p=0.640) and cardiac death (1.3% versus 1.6%, respectively; p=0.659) were not different between groups. Rates of target-vessel MI (3.0% versus 3.8%, respectively; p=0.382) and clinically indicated TLR (4.7% versus 5.3%, respectively; p=0.627) were also similar between groups. Definite/probable stent thrombosis rates remained very low and similar in the Supraflex and Xience groups (1.1% versus 1.3%, respectively; p=0.813).

Although clinical outcomes are limited, the first results of the Supraflex stent are promising. Importantly, the Supraflex Cruz, Everolflex, Tetrixflex and Tetrilimus stents have not yet been randomly compared with other DES.

BioMime™

In the merIT-V randomized trial (NCT02112981), 256 patients from 15 centres throughout Europe were randomized in a 2:1 fashion to either the BioMime stent or the Xience stent. Patients initially diagnosed with MI were excluded. Lesion length up to 44 mm was allowed, with a maximum of two lesions. Complex lesions (e.g. severely calcified lesions, bifurcations, restenotic or left main lesions) were excluded. The primary endpoint was non-inferiority of the BioMime stent to the Xience stent with regard to in-stent late lumen loss at 9 months. The study met its primary endpoint: in-stent late lumen loss was 0.15 ± 0.27 mm (mean ± SD) in the BioMime group and 0.15 ± 0.29 mm in the Xience group (difference, -0.006 mm; 95% CI, -0.085 to 0.072; p for non-inferiority <0.0001). MACE rate, defined as the composite of cardiac death, MI and ischaemia-driven TLR was numerically lower in the BioMime group than the Xience group (2.98% versus 7.14%, respectively; p=0.13), driven by a statistically significant between-group difference in the occurrence of MI (0.6% in the BioMime group versus 4.8% in the Xience group; p=0.03). However, there was no difference in target vessel-related MI rates (0.6% in the BioMime group versus 1.2% in the Xience group; p=0.62) and definite/probable stent thrombosis rates (0% in both groups) between groups.

Although these angiographic results are promising and may lead to excellent and comparable revascularization rates compared with other DES, clinical trials powered for clinical endpoints are needed to confirm this.

Meta-analysis

The above-described randomized trials have been included in a recent meta-analysis. In total, 16 randomized trials comparing ultrathin-strut DES with second-generation DES were included in the analysis. A total of 20,701 patients were included, and the mean follow-up duration was 2.5 years. TLF was defined as the composite of cardiac death, MI or clinically driven TLR. DES with ultrathin struts, compared with second-generation DES, were associated with a significant 15% reduction in TLF (relative risk, 0.85; 95% CI, 0.76–0.96; p=0.008) (Figure 3). This was mainly due to a significant 25% reduction in clinically driven TLR rate (relative risk, 0.75; 95% CI, 0.62–0.92; p=0.005) (Figure 3). Clinically driven TLR rate was also lower with the ultrathin-strut DES (relative risk, 0.84; 95% CI, 0.74–0.95; p=0.006). There were no significant differences with regard to other components individually (MI, stent thrombosis, and cardiac death) (Figure 3).

Conclusions

DES with ultrathin struts (<70 µm) have shown promising clinical results in further improving clinical outcomes after PCI. Individual randomized trials (mainly involving the Orsiro DES) have consistently shown that ultrathin-strut DES with biodegradable polymers are non-inferior to second-generation DES, mainly the Xience DES, eluting everolimus from a durable polymer with strut thickness of 81 µm. In a recent meta-analysis, there was a statistically significant long-term (2.5 years) clinical improvement with the ultrathin-strut DES compared with the second-generation DES in terms of TLF and TVF, driven by differences in
TLR and TVR rates. However, the relative risk reduction of 15% in both TLR and TLF was modest, and absolute risk reduction was low given the already very favourable results with second-generation DES (~8.3% of TLF in the control group at 2.5 years). This means that, in absolute terms, reduction in TLF was modest (~1.2%). Furthermore, in terms of safety, MI and cardiac death rates were not statistically significantly reduced. In patients with STEMI, the Orsiro stent may be superior to other non-ultrathin second-generation DES. On the other hand, in some lesions, such as heavily calcified lesions or CTOs (as shown in PRISON II), the ultrathin-strut stents may perform less favourably than their second-generation counterparts using the same alloy but thicker struts, although more studies are needed to clarify this.

In conclusion, the newest generation ultrathin-strut DES with biodegradable polymers are ‘here to stay’ as an attractive alternative to other second- and third-generation DES.
61. Gao C, Kogame N, Sharif F, et al. Prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the ultra-thin strut sirolimus-eluting coronary stent Supraflex: two-year outcomes of the TALENT trial. Circ Cardiovasc Interv. 2021;14:e010312.

62. Abizaid A, Kediev S, Kedhi E, et al. Randomized comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the merIT-V trial. EuroIntervention. 2018;14:e1207–14.

63. Madhavan MV, Howard JP, Naqvi A, et al. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2021;42:2643–54.